---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-014382"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:14:54.471095+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%

## Summary
- Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.
- GAAP net loss $0.10/shr; non-GAAP adjusted net loss $0.05/shr vs adjusted net income $0.09/shr in Q1 2023.
- Cash, cash equivalents and marketable securities $107.2M at March 31, 2024; operating cash flow $11.3M.
- Q2 2024 guidance: net product revenue $43-45M, net loss $(6)-(9)M; FY2024: product revenue $183-190M, net income $12-15M.
- Initiated alisertib Phase II trial in small cell lung cancer (ALISCA-Lung1); key milestones through Q4 2024.

## SEC filing metadata
- accession: 0001437749-24-014382
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/0001437749-24-014382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/pbyi20240430_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-014382
- JSON: https://secwatch.observer/filing/0001437749-24-014382.json
- Plain text: https://secwatch.observer/filing/0001437749-24-014382.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported the first quarter ended March 31, 2024 results: revenue $43.8 million, net income net loss of $4.8 million, EPS $0.10 per basic and diluted share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $43.8 million
  - Net income: net loss of $4.8 million
  - EPS: $0.10 per basic and diluted share
  - Result: reported results
  source text: sales of NERLYNX, Puma’s first commercial product, license revenue from Puma’s sub-licensees and royalty revenue. For the first quarter ended March 31, 2024, total revenue was $43.8 million, of which $40.3 million was net product revenue and $3.5 million was royalty revenue. This compares to total revenue of $52.8 million in the first quarter of 2023, of which $46.8
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/0001437749-24-014382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.